Jean-Pierre J Issa Selected Research

Decitabine

10/2017	Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.
5/2017	DNA Hypomethylating Drugs in Cancer Therapy.
1/2017	Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome.
1/2015	Epigenetic synergy between decitabine and platinum derivatives.
1/2011	Mechanisms of resistance to decitabine in the myelodysplastic syndrome.
9/2010	Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation.
6/2009	Targeting DNA methylation.
1/2009	Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines.
2/2008	Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia.
9/2007	Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jean-Pierre J Issa Research Topics

Disease

79	Neoplasms (Cancer) 06/2019 - 01/2002
15	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 06/2019 - 04/2006
15	Colorectal Neoplasms (Colorectal Cancer) 12/2015 - 01/2003
9	Leukemia 01/2017 - 06/2002
9	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2016 - 07/2002
8	Breast Neoplasms (Breast Cancer) 01/2021 - 08/2003
8	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2019 - 03/2004
8	Colonic Neoplasms (Colon Cancer) 01/2017 - 01/2002
6	Myeloid Leukemia (Leukemia, Myelocytic) 05/2017 - 05/2006
6	Carcinogenesis 11/2010 - 01/2004
4	Melanoma (Melanoma, Malignant) 12/2015 - 08/2006
4	Adenoma (Adenomas) 02/2014 - 04/2005
4	Chromosomal Instability (Chromosome Stability) 04/2009 - 11/2003
3	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 07/2015 - 01/2007
3	Stomach Neoplasms (Stomach Cancer) 10/2013 - 12/2003
3	Prostatic Neoplasms (Prostate Cancer) 06/2008 - 07/2007
3	Microsatellite Instability 05/2008 - 05/2003
3	Philadelphia Chromosome 11/2007 - 07/2002
2	Triple Negative Breast Neoplasms 06/2021 - 01/2018
2	Adenocarcinoma of Lung 01/2021 - 12/2009
2	Adenocarcinoma 01/2021 - 12/2009
2	Infections 02/2014 - 08/2006
2	Glioma (Gliomas) 07/2013 - 04/2011
2	Urinary Bladder Neoplasms (Bladder Cancer) 07/2011 - 07/2007
2	Adenomatous Polyposis Coli (Familial Adenomatous Polyposis) 05/2008 - 04/2005
2	Acute Promyelocytic Leukemia 12/2007 - 10/2006
2	Myeloproliferative Disorders (Myeloproliferative Disorder) 11/2007 - 11/2005
2	Hematologic Neoplasms (Hematological Malignancy) 02/2007 - 03/2004
2	Carcinoma (Carcinomatosis) 04/2005 - 05/2003
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 03/2004 - 02/2003
1	Hyperplasia 01/2021
1	Adenocarcinoma in Situ 01/2021
1	Pain (Aches) 01/2018
1	Hypersensitivity (Allergy) 01/2018
1	Neuralgia (Stump Neuralgia) 01/2018
1	Ovarian Neoplasms (Ovarian Cancer) 01/2017

Drug/Important Bio-Agent (IBA)

29	DNA (Deoxyribonucleic Acid)IBA 06/2021 - 01/2002
23	Decitabine FDA Link 10/2017 - 03/2004
15	hydrogen sulfite (bisulfite)IBA 01/2021 - 05/2002
12	ChromatinIBA 02/2017 - 08/2003
11	MethyltransferasesIBA 01/2019 - 05/2003
11	Histones (Histone)IBA 01/2017 - 01/2002
10	Pharmaceutical PreparationsIBA 06/2019 - 03/2004
7	Azacitidine (5 Azacytidine)FDA Link 10/2017 - 05/2006
7	Calcibiotic Root Canal SealerIBA 02/2014 - 01/2004
6	guadecitabineIBA 06/2019 - 09/2015
6	Protein Isoforms (Isoforms)IBA 08/2017 - 01/2004
6	Estrogen ReceptorsIBA 01/2017 - 05/2002
6	Histone Deacetylase InhibitorsIBA 01/2017 - 08/2003
6	Imatinib Mesylate (Gleevec)FDA Link 01/2011 - 07/2002
5	Biomarkers (Surrogate Marker)IBA 01/2021 - 04/2008
5	Proteins (Proteins, Gene)FDA Link 04/2011 - 10/2006
5	CytosineIBA 05/2008 - 01/2002
3	Hormones (Hormone)IBA 01/2018 - 01/2007
3	Histone Deacetylases (Histone Deacetylase)IBA 01/2017 - 12/2007
3	Biological ProductsIBA 02/2014 - 12/2012
3	retinoic acid receptor betaIBA 06/2009 - 05/2003
3	Lysine (L-Lysine)FDA Link 06/2008 - 08/2003
3	Tretinoin (Retinoic Acid)FDA LinkGeneric 12/2007 - 04/2004
3	A-Form DNA (A-DNA)IBA 06/2005 - 12/2003
2	EnzymesIBA 01/2016 - 01/2010
2	Transcription Factors (Transcription Factor)IBA 07/2015 - 10/2005
2	PlatinumIBA 01/2015 - 01/2015
2	Glial Cell Line-Derived Neurotrophic Factor (GDNF)IBA 10/2013 - 06/2009
2	Retroelements (Retrotransposon)IBA 10/2012 - 10/2010
2	Progesterone Receptors (Progesterone Receptor)IBA 06/2012 - 06/2011
2	Cadherins (E-Cadherin)IBA 01/2010 - 06/2004
2	GuanineIBA 05/2008 - 02/2003
2	promyelocytic leukemia-retinoic acid receptor alpha fusion oncoproteinIBA 12/2007 - 10/2006
2	Messenger RNA (mRNA)IBA 11/2007 - 05/2006
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 11/2007 - 08/2006
2	Cyclin-Dependent Kinases (cdk Proteins)IBA 05/2003 - 04/2002
2	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 05/2003 - 05/2002
2	T-Type Calcium Channels (T-Type Calcium Channel)IBA 05/2003 - 05/2002
2	bcr-abl Fusion ProteinsIBA 07/2002 - 07/2002
1	Cell-Free Nucleic AcidsIBA 01/2021
1	Immune Checkpoint InhibitorsIBA 11/2018
1	Unithiol (DMPS)IBA 10/2018
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2018
1	RG108IBA 01/2018
1	GSK343IBA 01/2017
1	Histone DemethylasesIBA 01/2017
1	RNA (Ribonucleic Acid)IBA 01/2017
1	UNC 0638IBA 01/2017
1	ProscillaridinIBA 01/2017
1	CalciumIBA 03/2016
1	Tyrosine Kinase InhibitorsIBA 01/2016
1	VemurafenibIBA 12/2015
1	acivicin (AT 125)IBA 09/2015
1	theasinensin AIBA 09/2015
1	5-hydroxymethylcytosineIBA 07/2015
1	5-Methylcytosine (5 Methylcytosine)IBA 07/2015
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2015
1	Platinum Compounds (Compounds, Platinum)IBA 01/2015
1	Green Fluorescent ProteinsIBA 01/2015

Therapy/Procedure

28	Therapeutics 11/2018 - 12/2003
5	Drug Therapy (Chemotherapy) 10/2017 - 10/2007
1	Ligation 01/2018
1	Precision Medicine 09/2017
1	Immunotherapy 05/2017